Post-Progression Outcomes After Pembrolizumab in Patients with NSCLC and High PD-L1 Expression: RealWorld Data from a European Cohort

被引：0

作者：

Metro, G. ^{[1
]}

Signorelli, D. ^{[2
]}

Rey-Cobo, J. ^{[3
]}

Banini, M. ^{[1
]}

Economopoulou, P. ^{[4
]}

Lo Russo, G. ^{[2
]}

Baxevanos, P. ^{[5
]}

Roila, F. ^{[1
]}

De Toma, A. ^{[2
]}

Banna, G. ^{[6
]}

Christopoulou, A. ^{[7
]}

Jimenez, B. ^{[8
]}

Collazo-Lorduy, A. ^{[8
]}

Linardou, H. ^{[9
]}

Calles Blanco, A. ^{[10
]}

Galetta, D. ^{[11
]}

Addeo, A. ^{[12
]}

Camerini, A. ^{[13
]}

Kosmidis, P. ^{[14
]}

Garassino, M. ^{[15
]}

Mountzios, G. ^{[16
]}

机构：

[1] Santa Maria Della Misericordia Hosp, Med Oncol, Perugia, Italy

[2] Fdn Irccs Ist Nazl Tumori Milan, Thorac Oncolgy Unit, Milan, Italy

[3] Univ Hosp Geneva, Med Oncol, Geneva, Switzerland

[4] Attikon Univ Hosp, Med Oncol, Athens, Greece

[5] St Savvas Anticanc Hosp, Athens, Greece

[6] Osped Cannizzaro, Catania, Italy

[7] Agios Andreas Gen Hosp, Patras, Greece

[8] Hosp Hm Sanchinarro, Madrid, Spain

[9] Metropolitan Hosp, Oncol Unit, Athens, Greece

[10] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[11] Clin Canc Ctr Giovanni Paolo Ii, Thorac Med Oncol Unit, Bari, Italy

[12] Hop Univ Geneve, Geneva, Switzerland

[13] Osped Versilia, Lucca, Italy

[14] Hygeia Hosp, Athens, Greece

[15] Fdn Irccs Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[16] Henry Dunant Hosp Ctr, Dept Med Oncol 2, Athens, Greece

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期

关键词：

Pembrolizumab; Real world data; post-progression outcomes;

D O I：

10.1016/j.jtho.2019.08.1235

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.16-09

引用

页码：S589 / S589

页数：1